Motapizone
Product Specifications
UNSPSC Description
Motapizone (NAT 05-239) is a selective PDE3 inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP[1][2].
Target Antigen
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/motapizone.html
Purity
95.0
Solubility
DMSO : 2.7 mg/mL (ultrasonic)
Smiles
CC(C1)C(C2=CC(N3C=CN=C3)=CS2)=NNC1=O
Molecular Weight
260.322
References & Citations
[1]Milara J, et al. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011 Apr;41(4):535-46. |[2]Borbe HO, et al. Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP. Agents Actions Suppl. 1986;20:249-57.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-106739/Motapizone-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-106739/Motapizone-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
90697-57-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1245048-01 0.05 mg (E-Coli)
Recombinant Enterocytozoon bieneusi Probable eukaryotic translation initiation factor 4 gamma homolog (EIF4G), partial
Ask
View Details MBS1245048-02 0.05 mg (Yeast)
Recombinant Enterocytozoon bieneusi Probable eukaryotic translation initiation factor 4 gamma homolog (EIF4G), partial
Ask
View Details